Artemis Hospitals, Gurugram, has achieved a significant international milestone with the Department of Nuclear Medicine being accredited as an ICPO Clinical Theranostics Center of Excellence. This recognition reflects the hospital’s commitment to delivering globally benchmarked precision oncology and advanced nuclear medicine care.
The accreditation has been achieved under the leadership of Dr. Noaline Sinha, Chairperson, Nuclear Medicine & Radio-Theranostics, further strengthening Artemis Hospitals’ position as a leading destination for advanced cancer diagnostics and targeted radioisotope therapies in India.
Understanding Theranostics: The Future of Precision Oncology
Theranostics is an advanced approach in cancer care that combines diagnosis and targeted therapy into a single, integrated treatment pathway. By using specialized radioactive tracers, physicians can precisely identify cancer cells, evaluate disease spread, and deliver highly targeted treatment directly to affected tissues.
- Personalized treatment planning
- Greater precision in cancer targeting
- Early and accurate disease detection
- Reduced impact on surrounding healthy tissues
- Improved monitoring of treatment response
Theranostics is increasingly transforming the management of complex cancers, particularly in conditions such as prostate cancer, neuroendocrine tumors, and other difficult-to-treat malignancies.
What the ICPO Accreditation Represents?
The International Centers for Precision Oncology (ICPO) accreditation is awarded to institutions that meet globally recognized standards in theranostics, molecular imaging, nuclear medicine infrastructure, patient safety, and multidisciplinary cancer care.
Being recognized as a Clinical Theranostics Center of Excellence demonstrates that Artemis Hospitals has fulfilled stringent international requirements for delivering advanced radioisotope therapies and precision oncology services.
This distinction places Artemis among a select group of healthcare institutions offering internationally benchmarked theranostics capabilities.
Advanced Radioisotope Therapies for Cancer Care
The Department of Nuclear Medicine at Artemis Hospitals offers advanced radioisotope-based therapies designed to target cancer cells with greater precision. These therapies are supported by specialized molecular imaging and nuclear medicine technologies that enable accurate diagnosis, targeted treatment planning, and continuous response assessment. The department focuses on delivering precision-driven cancer care through:
- Advanced molecular imaging and theranostics expertise
- State-of-the-art PET-CT and nuclear medicine infrastructure
- Personalized treatment pathways
- Integrated multidisciplinary oncology care
- Internationally aligned clinical protocols
- Patient-centric precision oncology solutions
Leadership Driving Clinical Excellence
The accreditation highlights the vision and leadership of Dr. Noaline Sinha, whose expertise in Nuclear Medicine and Radio-Theranostics has played a pivotal role in advancing precision oncology services at Artemis Hospitals.
Under her guidance, the department continues to focus on innovation, clinical excellence, and the integration of cutting-edge theranostics solutions aimed at improving patient outcomes and expanding access to advanced cancer therapies.
What This Recognition Means for Artemis Hospitals
The ICPO Clinical Theranostics Center of Excellence accreditation marks an important step forward in Artemis Hospitals’ journey toward advancing precision oncology and nuclear medicine in India. It reflects the institution’s continued investment in advanced medical technologies, specialized expertise, and globally benchmarked treatment standards.
This international recognition reinforces Artemis Hospitals’ commitment to offering integrated cancer care solutions that combine diagnostics, molecular imaging, targeted therapies, and multidisciplinary clinical expertise under one platform.
It also highlights the hospital’s growing role in strengthening the future of precision oncology in India by making advanced theranostics and radioisotope therapies more accessible to patients seeking highly specialized cancer care.
Why Choose Artemis Hospitals for Theranostics and Precision Oncology?
Artemis Hospitals combines advanced technology, experienced specialists, and patient-focused care to deliver comprehensive precision oncology services. The ICPO accreditation further validates the hospital’s capability to provide high standards of safety, clinical excellence, and specialized theranostics care. Key differentiators include:
- Internationally accredited theranostics and nuclear medicine services
- Expertise in advanced radioisotope therapies for complex cancers
- Integrated approach combining diagnostics, molecular imaging, and targeted treatment
- Access to advanced PET-CT and nuclear medicine infrastructure
- Multidisciplinary collaboration between oncology, radiology, nuclear medicine, and surgical teams
- Personalized treatment planning tailored to individual patient needs
- Focus on innovation, research-driven care, and global best practices
As cancer care continues to evolve toward precision medicine, Artemis Hospitals remains committed to delivering advanced, globally aligned oncology solutions designed to improve clinical outcomes and enhance the overall patient care experience.
